JP2024532836A5 - - Google Patents

Info

Publication number
JP2024532836A5
JP2024532836A5 JP2024509425A JP2024509425A JP2024532836A5 JP 2024532836 A5 JP2024532836 A5 JP 2024532836A5 JP 2024509425 A JP2024509425 A JP 2024509425A JP 2024509425 A JP2024509425 A JP 2024509425A JP 2024532836 A5 JP2024532836 A5 JP 2024532836A5
Authority
JP
Japan
Prior art keywords
seq
fusion protein
amino acid
acid sequence
tgf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024509425A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024532836A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/113882 external-priority patent/WO2023020625A1/zh
Publication of JP2024532836A publication Critical patent/JP2024532836A/ja
Publication of JP2024532836A5 publication Critical patent/JP2024532836A5/ja
Pending legal-status Critical Current

Links

JP2024509425A 2021-08-20 2022-08-22 抗TIGIT抗体及びTGF-βRを含む融合タンパク質、並びにその医薬組成物及び使用 Pending JP2024532836A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110961038.5 2021-08-20
CN202110961038 2021-08-20
PCT/CN2022/113882 WO2023020625A1 (zh) 2021-08-20 2022-08-22 包含抗TIGIT抗体和TGF-βR的融合蛋白、其药物组合物及用途

Publications (2)

Publication Number Publication Date
JP2024532836A JP2024532836A (ja) 2024-09-10
JP2024532836A5 true JP2024532836A5 (cg-RX-API-DMAC7.html) 2024-11-12

Family

ID=85239528

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024509425A Pending JP2024532836A (ja) 2021-08-20 2022-08-22 抗TIGIT抗体及びTGF-βRを含む融合タンパク質、並びにその医薬組成物及び使用

Country Status (11)

Country Link
US (1) US20250319169A2 (cg-RX-API-DMAC7.html)
EP (1) EP4389771A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024532836A (cg-RX-API-DMAC7.html)
KR (1) KR20240046905A (cg-RX-API-DMAC7.html)
CN (1) CN116003625A (cg-RX-API-DMAC7.html)
AU (1) AU2022330896A1 (cg-RX-API-DMAC7.html)
CA (1) CA3229166A1 (cg-RX-API-DMAC7.html)
IL (1) IL310541A (cg-RX-API-DMAC7.html)
MX (1) MX2024002147A (cg-RX-API-DMAC7.html)
WO (1) WO2023020625A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202401813B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230098221A (ko) * 2020-10-26 2023-07-03 아케소 바이오파마, 인크. 항-tigit 항체, 약학 조성물 및 이의 용도
IL322840A (en) * 2023-02-20 2025-10-01 Akeso Biopharma Co Ltd Fusion protein comprising a TGF-βRII extracellular region fragment, its pharmaceutical composition and use
KR20260074706A (ko) * 2023-09-14 2026-05-26 아케소 바이오파마 컴퍼니 리미티드 약물 조합 및 그 용도

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JO3096B1 (ar) * 2008-11-07 2017-03-15 Imclone Llc الأجسام المضادة لمستقبل ii مضاد tgfb
AR103268A1 (es) * 2014-12-23 2017-04-26 Bristol Myers Squibb Co Anticuerpos contra tigit
CA2998589A1 (en) * 2015-09-14 2017-03-23 Compass Therapeutics Llc Compositions and methods for treating cancer via antagonism of the cd155/tigit pathway and tgf-.beta.
SG10202007764TA (en) 2015-09-25 2020-09-29 Genentech Inc Anti-tigit antibodies and methods of use
MX2018008416A (es) * 2016-01-08 2019-11-11 Univ California Polipéptidos heterodímericos condicionalmente activos y métodos para su uso.
MX2018010485A (es) * 2016-03-04 2019-01-10 Jn Biosciences Llc Anticuerpos para inmunoreceptor de celulas t con dominios de ig e itim (tigit).
CN110050000B (zh) * 2017-05-12 2022-07-26 苏州盛迪亚生物医药有限公司 含有TGF-β受体的融合蛋白及其医药用途
CN111051347B (zh) * 2017-09-29 2021-12-21 江苏恒瑞医药股份有限公司 Tigit抗体、其抗原结合片段及医药用途
JP7348899B2 (ja) * 2017-12-08 2023-09-21 マレンゴ・セラピューティクス,インコーポレーテッド 多重特異性分子及びその使用
JP7316284B2 (ja) * 2018-01-15 2023-07-27 ナンジン レジェンド バイオテック カンパニー,リミテッド Tigitに対する抗体及びその多様体
JP2022537068A (ja) * 2019-06-23 2022-08-23 グアンドン ティーシーアールキュア バイオファーマ テクノロジー カンパニー リミテッド 抗alpp car-t細胞療法
US20230340122A1 (en) * 2019-11-05 2023-10-26 Glaxosmithkline Intellectual Property (No. 4) Ltd. Combined inhibition of pd-1, tgfb and tigit for the treatment of cancer
TW202128763A (zh) * 2019-11-12 2021-08-01 大陸商江蘇恆瑞醫藥股份有限公司 含有TGF-β受體的融合蛋白及其醫藥用途
EP4061951A4 (en) * 2019-11-18 2024-03-13 The Brigham & Women's Hospital, Inc. CODON-OPTIMIZED NEW GENERATION OF REGULAtable FUSOGENIC ONCOLYTIC VIRUSES OF HERPES SIMPLEX VIRUS TYPE 1 AND METHOD OF USE
KR20230098221A (ko) * 2020-10-26 2023-07-03 아케소 바이오파마, 인크. 항-tigit 항체, 약학 조성물 및 이의 용도
CN114106182B (zh) * 2022-01-26 2022-05-17 中山康方生物医药有限公司 抗tigit的抗体及其用途
CN114181310B (zh) * 2022-02-14 2022-07-05 中山康方生物医药有限公司 抗tigit抗体、其药物组合物及用途

Similar Documents

Publication Publication Date Title
US11136413B2 (en) PDL-1 antibody, pharmaceutical composition thereof, and uses thereof
CN115551888B (zh) 抗cd73抗体及其用途
KR102937285B1 (ko) 신규 항-pd-l1 항체
CN114181310B (zh) 抗tigit抗体、其药物组合物及用途
CN101868478B (zh) 巨噬细胞刺激蛋白质受体(ron)的抑制及其治疗方法
AU2018447127A1 (en) Anti-cldn18.2 antibody and uses thereof
AU2017279046A1 (en) Therapeutic uses of a c-Raf inhibitor
JP2022509156A5 (cg-RX-API-DMAC7.html)
JP2023539501A5 (cg-RX-API-DMAC7.html)
JP2023546743A5 (cg-RX-API-DMAC7.html)
CN107614010A (zh) 结合至flt3蛋白的抗体药物偶联物(adc)
JP2025511289A5 (cg-RX-API-DMAC7.html)
JP2024538669A5 (cg-RX-API-DMAC7.html)
JP2025511288A5 (cg-RX-API-DMAC7.html)
EP4506360A1 (en) Anti-pvrig antibody, pharmaceutical composition thereof and use thereof
CN116925233A (zh) 抗tigit-抗pvrig双特异性抗体、其药物组合物及用途
US9358288B2 (en) Antibody combinations and use of same for treating cancer
JP2024533457A5 (cg-RX-API-DMAC7.html)
JP2025516590A5 (cg-RX-API-DMAC7.html)
JP2024508597A5 (cg-RX-API-DMAC7.html)
WO2016163433A1 (ja) 抗fgfr2抗体と他剤を含む組成物
RU2024103139A (ru) Слитый белок, содержащий антитело против TIGIT и TGF-βR, фармацевтическая композиция и ее применение
WO2023227115A1 (en) A method of treating solid tumor
RU2025124380A (ru) СЛИТЫЙ БЕЛОК, СОДЕРЖАЩИЙ ФРАГМЕНТ ВНЕКЛЕТОЧНОЙ ОБЛАСТИ TGF-βRII, ЕГО ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ЕГО ПРИМЕНЕНИЕ
HK40089230A (en) Pharmaceutical composition and use